This study followed 206 prostate cancer patients for a median of just 16.5 years. They all received either Lupron or Zoladex along with radiotherapy. They also received the anti-androgen flutamide (Eulexin) at various doses and for varying lengths of time. Men with moderate to severe comorbidities showed no survival benefit from flutamide. For those without comorbidities there was no benefit for having 6 instead of just 4 months of the anti-androgen. This study though is dated in that flutamide is rarely used these days because of a high risk of liver toxicity for men on that drug.
Sanford NN, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV. 2016. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Prostate Cancer Prostatic Dis [Epub ahead of print] 8 November 2016. www.ncbi.nlm.nih.gov/pubmed/27824043